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Introduction
The clinical availability of tumor necrosis factor (TNF)
inhibitors has markedly improved the treatment of patients
with rheumatoid arthritis (RA) [1,2]. Members of this class
of agents have been shown to reduce symptoms, inhibit
structural damage, and improve physical function in
patients with RA. Infliximab (Remicade®; Centocor, Inc.,
Malvern, PA, USA), etanercept (Enbrel®; Immunex Corp,
Seattle, WA, USA), and adalimumab (Humira™; Abbott
Laboratories, Abbott Park, IL, USA) have been approved by
the US Food and Drug Administration (FDA) for the treat-
ment of patients with active RA [3–5]. (Adalimumab was
approved by the US FDA on 31 December 2002, after the
meeting of the American College of Rheumatology.)
Although no direct comparisons of these agents have
been made in large clinical trials, an extensive safety data-
base has been developed. This article provides an
overview of the safety of anti-TNF agents as a class and
individually.
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Abstract
Tumor necrosis factor (TNF) antagonists are biologic response modifiers that have significantly
improved the outcomes in patients with rheumatoid arthritis (RA). At this report, safety data were
collected on approximately 271,000 patients administered infliximab (as of February 2002), 121,000
patients administered etanercept (as of December 2001), and on 2400 patients who received
adalimumab in trials in connection with the regulatory approval process (approval granted December
2002 in the US and September 2003 in European Union). Infliximab and etanercept have predictable
and manageable safety profiles, and preliminary data suggest that the profile of adalimumab is
comparable. Safety issues involving the anti-TNF agents as a class include the risk of injection-site
reactions or infusion-related reactions, infection (for example, serious, opportunistic, or tubercular),
malignancy, autoimmunity, and demyelinating and neurologic disorders. Injection-site and infusion-
related reactions are most often easily managed and rarely lead to discontinuation of therapy.
Infections can be minimized or prevented by screening and careful monitoring and follow-up; most
infections respond to appropriate medical treatment. More studies are needed to evaluate the
occurrence of malignancies in patients with RA to determine the potential risk posed by therapy.
Antibody formation can follow the administration of any biologic agent. Although demyelinating disease
has been reported with anti-TNF agents, it is not clear whether a causal relationship exists. Overall, the
anti-TNF agents are well tolerated and have demonstrated a favorable benefit-to-risk profile in patients
with RA.
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Use and safety of anti-TNF agents
Since their introduction, infliximab and etanercept have
become widely used biologic agents for the treatment of
patients with RA. Together, nearly 400,000 patients have
now used these agents, with approximately 271,000
patients having been administered infliximab as of Febru-
ary 2002 (data on file, Centocor, Inc.) and approximately
121,000 patients having received etanercept as of
December 2001 (data on file, Immunex Corp). Safety data
for adalimumab are limited to phase I and early phase II
data, which are proprietary, and late phase II and III data,
which have been presented at rheumatology congresses;
since approval approximately 2400 patients have received
adalimumab (data on file, Abbott Laboratories).
TNF is an important proinflammatory cytokine that induces
immunologic changes, including the production of other
cytokines, the expression of adhesion molecules, and the
release of procoagulant substances [6]. TNF also partici-
pates in host resistance, thus raising concern that anti-
TNF agents might be associated with an increased risk of
infection and malignancy. Other concerns about the use of
these agents in patients with RA include the risk of
autoimmune disorders, demyelination, and neurologic
events [7].
Adverse events
The anti-TNF agents are biologic response modifiers that
have been developed for parenteral administration. Inflix-
imab is administered intravenously, and etanercept and
adalimumab are administered subcutaneously [3–5]. Many
of the adverse events (AEs) discussed below are related
mainly to the administration of these drugs (e.g. injection-
site reactions, infusion-related reactions).
Etanercept
Because etanercept (Enbrel®, Immunex Corp) was the
first anti-TNF agent introduced (November 1998), it has
been studied the most extensively. Among AEs reported in
3% or more of all patients in placebo-controlled and
active-controlled RA clinical trials of etanercept, the most
frequently encountered have been injection-site reactions,
which were reported in 37% of etanercept-treated
patients versus 10% of controls in placebo-controlled
trials, and 34% of etanercept-treated patients versus 7%
of controls in active-controlled trials (Table 1) [3]. These
reactions are generally mild-to-moderate, occur sporadi-
cally (in an average of 4 of approximately 104 injections
yearly) and do not necessitate the discontinuation of the
agent [3,8]. In controlled trials, upper respiratory tract
infections (URIs) were the most common type of infection,
occurring in approximately 20% of etanercept-treated
patients and controls [3].
Adalimumab
The Safety Trial of Adalimumab in Rheumatoid Arthritis
(STAR) was a 24-week study that evaluated the safety
and efficacy of adalimumab (Humira™; Abbott Laborato-
ries) in combination with standard-of-care therapy (namely
disease-modifying antirheumatic drugs [DMARDs], corti-
costeroids, and non-steroidal anti-inflammatory drugs
[NSAIDs]) in 636 patients with active RA [9]. The safety
results of this trial showed no significant difference in the
incidence of AEs between adalimumab-treated patients
and controls (86.5% versus 82.7%) [9]. AEs were catego-
rized as non-infectious or infectious. Among the non-infec-
tious AEs, injection-site reactions were the most
commonly reported, occurring in 19.5% of adalimumab-
treated patients and 11.6% of controls (P<0.05; Table 2)
(data on file, Abbott Laboratories). Infections reported as
AEs included URIs, sinusitis, and the influenza syndrome.
URIs were reported most frequently (19.8% of adali-
mumab-treated patients versus 15.1% of controls) (data
on file, Abbott Laboratories).
Keystone and colleagues conducted a 52-week, double-
blind, randomized trial to evaluate the efficacy and safety
of adalimumab in 619 patients who had active RA despite
methotrexate therapy [10]. Patients were randomized to
receive adalimumab subcutaneously 20mg weekly or
40mg every 2 weeks, or placebo. Efficacy results at
52 weeks showed a significant response in clinical mea-
sures of disease activity (for example, tender joint counts)
and significant differences between adalimumab and
placebo in radiographic end points (namely Sharp score,
Table 1
Injection-site reaction in controlled clinical trials of etanercept
Placebo-controlled Active-controlled
patients (%) patients (%)
Etanercept Placebo Etanercept Methotrexate
Event (n=349) (n=152) (n=415) (n=217)
Injection-site reaction 37 10 34 7
Data from [3].
Table 2
Injection-site reaction in the STAR trial
Patients (%)
Adalimumab Placebo
+SOC +SOC
Event (n=318) (n= 318) P
Injection-site reaction 19.5 11.6 <0.05
More than one occurrence per patient is possible. Injection-site
reactions were the most frequent reported non-infection adverse event.
Data on file, Abbott Laboratories, Abbott Park, IL, USA.
STAR, Safety Trial of Adalimumab in Rheumatoid Arthritis; 
SOC, standard of care.S14
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erosion score, joint-space narrowing score) [10]. Safety
results showed injection-site reactions (erythema, itching,
hemorrhage, pain or swelling at the site of injection) to be
the most frequently reported AE, occurring in a similar per-
centage of patients in the adalimumab and placebo
groups (22.9% and 23.5%, respectively) [5]. The rate of
withdrawals due to AEs was 10.0% among adalimumab-
treated patients compared with 6.5% among placebo-
treated patients [10].
Infliximab
Although infliximab has been used for a shorter time than
etanercept, it has been administered to almost twice as
many patients. As a result, the number of patient-years of
the use of these agents can be considered comparable.
Because infliximab is administered intravenously, patients
can develop an infusion-related reaction rather than an
injection-site reaction. Infusion-related reactions are
defined as AEs occurring within 1–2 hours of infusion
therapy [4].
Clinical trial data have shown that 22% of infliximab-
treated patients have experienced an infusion reaction
compared with 9% of controls [4]. Considering that a
patient with RA might receive more than one infusion of
infliximab over time, another way of determining how often
infusion reactions have occurred in clinical trials of inflix-
imab is to divide the number of infusions that resulted in
infusion reactions by the total number of reactions. Clinical
trial data from 1678 infliximab-treated patients and 731
placebo-treated subjects show that 4.8% of infliximab
infusions resulted in infusion reactions (537 infusions with
reactions/11,253 total infusions) compared with 2% of
placebo infusions (85 infusions with reactions/4183 total
infusions; data on file, Centocor, Inc.). However, fewer than
1% of infliximab-treated patients develop serious infusion-
related reactions, and only 2.5% of reactions result in a
discontinuation of therapy (data on file, Centocor, Inc.).
Infusion-related reactions are generally mild and non-
specific, can usually be prevented or easily managed, and
seem not to be related to changes in dose or frequency of
administration (Fig.1) [4,11–14]. As with etanercept and
adalimumab, the most frequently reported infectious AEs
in infliximab-treated patients are URIs; they have been
shown to occur with a similar incidence between treated
patients and controls (34% versus 33%) [4].
Symptomatic injection-site reactions can be managed with
warm compresses and oral antihistaminics. Acute infusion
reactions generally respond to a decrease in the rate of infu-
sion of the drug [15]. Pretreatment with an oral H1 blocker
such as diphenhydramine (25–50mg) and acetaminophen
(500–1000mg) can be used to prevent many of the symp-
toms [16]. Viral URIs are usually self-limiting, whereas bac-
terial URIs generally respond to oral antibiotic therapy.
Infection
Factors predisposing patients to infection include the use
of concomitant immunosuppressant therapy and the
severity of the underlying inflammatory disease [17].
Etanercept
The incidence of serious infections (namely infections
requiring hospitalization or parenteral antibiotics) in
patients with RA before the anti-TNF era ranged from
approximately 0.02 to 0.12 per patient-year [18–21]. Clini-
cal data have shown the incidence of serious infections in
patients treated with etanercept to be 0.041 per patient-
year, or approximately 1%, which is similar to the incidence
reported in controls (data on file, Immunex Corp). Postmar-
keting data have indicated an incidence of 0.007 serious
infections per patient-year in etanercept-treated patients,
although under-reporting cannot be discounted (data on
file, Immunex Corp). Postmarketing studies of etanercept
have also yielded reports of sepsis and death, sometimes
occurring within weeks of initiation of therapy (data on file,
Immunex Corp) [3]. For this reason it is important not to
institute etanercept therapy in patients with an active infec-
tion or in those with chronic infections, and to withhold
therapy in patients who develop a serious infection.
Tuberculosis (TB) has been reported in patients receiving
anti-TNF agents; it remains the subject of safety surveil-
lance in the use of these agents [22]. Although no cases
of TB occurred in etanercept-treated patients during clini-
cal trials, there have been 20 confirmed cases of etaner-
cept-associated TB worldwide since the drug was
approved (data on file, Immunex Corp). Of those cases,
75% occurred in the USA, which has reported approxi-
Figure 1
Infusion reactions by dosage of infliximab as reported in the ATTRACT
study. All patients received concomitant methotrexate. ATTRACT, Anti-
Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant
Therapy [12–14].S15
mately 14.3 cases per 100,000 etanercept-treated
patients; the remainder came from Europe. (To place this
in perspective, the incidence of TB in the USA, as
reported by the most recent data from the Centers for
Disease Control and Prevention, is 6.2 cases per 100,000
population [23]). It is not known what the incidence of TB
is in the RA population not treated with anti-TNF agents.
Of the 20 cases, 85% were of localized disease. In post-
marketing reports, serious infections, including TB, and
sepsis have been reported with etanercept. Close moni-
toring is advised for patients who develop a new infection
while undergoing therapy with etanercept. Treatment
should not be initiated in those with active infections,
including chronic or localized infections [3].
Postmarketing data have also reported serious opportunis-
tic infections in etanercept-treated patients (data on file,
Immunex Corp). Fungal (Histoplasma, Aspergillus, Candida,
Cryptococcus, Sporothrix), viral (cytomegalovirus), bacterial
(Listeria), and protozoal (Pneumocystis) infections have
been noted in all organ systems of patients receiving etaner-
cept as monotherapy or in combination with immunosup-
pressive agents [3].
Adalimumab
In placebo-controlled trials, the incidence of serious infec-
tions, including TB, in adalimumab-treated patients (0.04 per
patient year) was similar to that in placebo-treated patients
(0.02 per patient year) [5]. The 13 cases of TB reported in
clinical trials with adalimumab included several types e.g. mil-
itary, lymphatic, peritoneal, and pulmonary TB [5].
However, in phase I trials in which adalimumab was
administered at 20-fold higher doses than that used in
current trials (approximately 40mg every 2 weeks),
researchers noted a 2.5% incidence of TB infections in
study participants (Table 3) (data on file, Abbott Laborato-
ries). In early phase II clinical trials, the dose of adali-
mumab was reduced to about four times the currently
used dose, and the incidence of TB dropped to 1%.
Patients had not been screened for TB in these trials
before the administration of adalimumab. In phase III trials
in which the dose of adalimumab was double that used in
current trials and in which chest X-ray was used to screen
for TB, no cases of TB were reported. These short-term
safety data for adalimumab suggest that the risk of reacti-
vation of latent TB is increased relative to controls.
No data on other opportunistic infections have yet been
made available, nor have there been any reports of such
infections. Postmarketing data will be needed for a full
evaluation of this potential risk.
Infliximab
Clinical data have shown the incidence of serious infec-
tions in patients treated with infliximab to be 0.030 infec-
tion per patient-year (data on file, Centocor, Inc.). Post-
marketing surveillance up to December 2001 has not
detected any change in this rate.
Opportunistic infections caused by viral, fungal, bacterial,
and protozoal pathogens have been observed with inflix-
imab. Data from postmarketing surveillance for infliximab
(used by 271,000 patients as of February 2002) and etan-
ercept (used by 121,000 patients as of September 2001)
indicate that an apparently greater number cases of
certain opportunistic infections – particularly Pneumocys-
tis infections and histoplasmosis – have been reported in
infliximab-treated patients (26 and 18 cases, respectively)
(data on file, Centocor, Inc.) than in etanercept-treated
patients (4 and 1 cases, respectively) (data on file,
Immunex Corp) [24].
As of February 2002, postmarketing surveillance indicates
181 confirmed cases of TB worldwide in patients who
have received infliximab (data on file, Centocor, Inc.). Most
(70%) of the reported cases have come from Europe, with
the remainder coming from the USA, where approximately
31 cases of TB have been reported per 100,000 patients
treated with infliximab. At the time of diagnosis, two-thirds
of the cases were non-disseminated. In most cases, TB
had developed by the time of the third infusion, suggesting
that the active infection might be a result of the reactiva-
tion of latent TB [7].
Precautions can be taken to prevent or minimize serious
infections that might occur while a patient is receiving anti-
TNF therapy. Anti-TNF agents should not be administered
to patients with clinically significant acute infections. In
addition, caution should be exercised when treating
patients with a chronic infection, a history of recurrent
infections, or a disease, such as poorly controlled diabetes
mellitus, that predisposes them to infection. If a patient
develops a serious infection, TNF antagonist therapy
should be discontinued until the infection has resolved. To
reduce the risk of opportunistic infections, a careful
risk–benefit assessment of anti-TNF therapy should be
Available online http://arthritis-research.com/content/6/S2/S12
Table 3
Impact of adalimumab dose and screening on tuberculosis
rates
Intensity Screening by Patients Tuberculosis
Trial phase of dosea chest X-ray tested cases
I ×20 No 198 5
II ×4 No 284 3
III ×2 Yes 511 0
aNumber of times above the commonly administered dose of 40mg
every 2 weeks. 
Data on file, Abbott Laboratories, Abbott Park, IL, USA.S16
made before such therapy is administered to patients who
reside in endemic areas; additionally, such patients need to
be monitored carefully during treatment. TB is a pre-
ventable disease; therefore, screening with purified protein
derivative or chest X-ray is extremely important.
Malignancy
Patients with RA who receive anti-TNF therapy might be at
an increased risk of malignancy. This is suggested by the
following: (1) the involvement of TNF in host defense
mechanisms, (2) the role of TNF as a modulator of cellular
immune responses, and (3) previous reports describing a
possible increased risk of certain cancers (such as lym-
phomas) in patients with RA [25–27]. Importantly, it is not
certain whether this increase was related to the disease
itself, the earlier antirheumatic therapies available, or other
factors.
Etanercept
The observed incidence of malignancy in etanercept-treated
patients in clinical trials conducted so far (41 cases) is
close to the expected incidence of malignancy in non-etan-
ercept-treated patients with RA (42 cases), on the basis of
findings from the National Cancer Institute Surveillance, Epi-
demiology, and End Results (SEER) database (data on file,
Immunex Corp). Additionally, no type of cancer was noted
to predominate in etanercept-treated patients. Longer-term
data might be needed to clarify the risk of malignancy, espe-
cially the risk of lymphoma, for patients with RA receiving
this anti-TNF therapy.
Adalimumab
The number of patients treated with adalimumab so far
might be too small, and the time for pharmacosurveillance
too short, to detect an association (or lack thereof)
between adalimumab and the incidence of malignancies.
In the STAR trial [9], malignancy developed in two
patients treated with adalimumab but not in the controls
(data on file, Abbott Laboratories).
Infliximab
On the basis of data from completed trials of infliximab for
up to 102 weeks, 18 of 1372 patients developed 19 new
or recurrent malignancies of various types over 1430
patient-years of follow-up [4]. New or recurrent malignan-
cies included non-Hodgkin’s B-cell lymphoma, breast
cancer, melanoma, squamous, rectal adenocarcinoma,
and basal-cell carcinoma. The observed rate of risk for
developing malignancy with infliximab-treated patients
(1.3%) was similar to that expected for non-infliximab-
treated patients with RA from a previous study (1.5%;
95% confidence interval 0.9–2.3) [4,28].
Although treatment with immunosuppressive agents is
linked to an increase in lymphoproliferative diseases, there
is no clear evidence that this is a direct consequence of
therapy with a TNF antagonist. Nonetheless, lymphadeno-
pathy in a patient treated with a TNF antagonist is an indi-
cation for follow-up and biopsy if the etiology is not known
and nodal enlargement persists or increases.
Autoimmunity
Antibody formation can follow the administration of bio-
logic agents such as the TNF antagonists. Immunologic
reactions that can occur with TNF blockade include the
development of neutralizing and non-neutralizing antibod-
ies and autoantibodies [2].
Etanercept
In randomized clinical trials, the development of new posi-
tive antinuclear antibodies (ANA, titer ≥1:40) was noted in
a greater percentage of patients treated with etanercept
than with placebo (11% versus 5%) [3]. On the basis of a
radioimmunoassay, new positive anti-double-stranded
deoxyribonucleic acid (anti-dsDNA) antibodies developed
in 15% of etanercept-treated patients compared with 4%
of placebo recipients [3]. Although there were no cases
suggestive of a lupus-like syndrome in clinical trials, post-
marketing surveillance has identified 16 such cases (data
on file, Immunex Corp).
Adalimumab
Although adalimumab is a fully human anti-TNF mono-
clonal antibody, antibodies against adalimumab have been
reported (data on file, Abbott Laboratories). However, no
data are currently available in the public domain.
Infliximab
The placebo-controlled, 102-week Anti-Tumor Necrosis
Factor Trial in Rheumatoid Arthritis with Concomitant
Therapy (ATTRACT) [12–14] showed that new positive
ANA (titer ≥1:40) developed during the period between
screening and last evaluation in a greater percentage of
infliximab-treated patients than in controls (62% versus
27%) [4]. Similarly, positive anti-dsDNA antibodies devel-
oped in a greater percentage of infliximab-treated patients
than in controls (13% versus 0%) [4]. The development of
both forms of antibodies in the infliximab-treated patients
was not associated with the dose or administration sched-
ule of the agent.
An analysis of the ATTRACT data [12–14] showed that
20% and 50% improvements in American College of
Rheumatology (ACR) criteria (that is, ACR20 and ACR50
responses, respectively) were reported by similar percent-
ages of patients who tested positive or negative for serum
antibody against infliximab [29]. ACR20 responses at 102
weeks were achieved by approximately 40% of patients
who demonstrated antibodies against infliximab at any
time during the study (n=25 of 295, or 8.5% of the total
patients in this analysis) compared with 38% of patients
with no antibodies against infliximab (n=105) and 62% of
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patients with inconclusive antibody status (n=165) [29].
ACR50 response rates at 102 weeks were 16%, 20%,
and 41% for the antibody-positive, antibody-negative, and
inconclusive antibody status groups, respectively [29].
The higher clinical response rates for the patients with
inconclusive antibody status were attributed to their main-
taining higher residual concentrations of infliximab [29,30].
In clinical studies with infliximab, three patients with RA
were diagnosed with a possible lupus-like syndrome [4].
There was no indication of central nervous system (CNS)
or renal involvement, and improvement followed the dis-
continuation of therapy and appropriate medical treatment
[4]. Importantly, no lupus-like reactions have been
observed in up to 3 years of long-term follow-up [4]. Post-
marketing data have identified a total of 39 cases of lupus-
like syndrome, all of which improved on discontinuation of
therapy (data on file, Centocor, Inc.). When interpreting
the data on immunologic events, it is important to remem-
ber that antibody development can be influenced by
several factors (such as immunogenic potential of the bio-
logic agent, route of administration, and repeated dosing)
and that assay methods to detect antibodies differ in their
sensitivity and specificity [31].
Demyelinating disorders and neurologic events
The epidemiology of demyelinating disorders in patients
with RA has not been definitively established. However,
there have been rare instances of new episodes and
exacerbations of CNS-demyelinating disorders and neuro-
logic events in patients with RA who were receiving anti-
TNF therapy.
Etanercept
Some of the demyelinating disorders have been observed
with etanercept. Indeed, the label for etanercept includes
a warning about the association of etanercept with rare
cases of new onset or exacerbation of demyelinating dis-
orders. Myelitis, optic neuritis, multiple sclerosis, and
seizure disorders have been observed in association with
etanercept therapy [3].
Adalimumab
In the clinical trials that have been conducted to date with
adalimumab, no heightened risk for developing demyeli-
nating disorders and neurologic events has been demon-
strated. However, this needs to be validated with data
from trials with longer duration of follow-up and from clini-
cal practice.
Infliximab
Postmarketing surveillance data for infliximab as of Febru-
ary 2002 indicate reports of central demyelination (n=8),
optic neuritis (n=6), and Guillain–Barré syndrome/
chronic inflammatory demyelinating polyradiculoneuropa-
thy in treated patients (n=4) (data on file, Centocor, Inc.).
Currently, there is no clear causal relationship between
demyelinating or neurologic disorders and anti-TNF
therapy. However, it makes good clinical sense to exercise
caution in prescribing these agents to certain patients,
such as those with pre-existing or recent-onset CNS-
demyelinating disorders.
Conclusion
The anti-TNF agents have been shown to achieve a marked
improvement in outcomes in patients with RA; in addition,
they are well tolerated. Safety concerns of rheumatologists,
about the use of anti-TNF agents, include the potential for
adverse events (such as injection-site reactions, infusion-
related reactions, or URIs), infections (such as serious,
opportunistic, or tubercular), malignancies, autoimmunity,
and demyelinating and neurologic disorders. Generally,
injection-site or infusion-related reactions are easily
managed and rarely lead to discontinuation of therapy.
Infections can be prevented and generally respond to
appropriate medical treatment. Hence, the value of screen-
ing and monitoring should be emphasized.
Antibody development can occur after the administration
of any biologic agent but, as Porter reports, “the presence
of antibodies does not necessarily mitigate against the
therapeutic viability of a recombinant protein drug” [31] as
has been demonstrated with anti-TNF agents [29]. No
causal relationship has been established between the
administration of anti-TNF agents and demyelinating disor-
ders or malignancies, although more studies are needed
to validate any potentially heightened risk. Overall, the TNF
biologic response modifiers have demonstrated a risk–
benefit profile that strongly favors benefit.
Choice of the optimal agent is based on accumulated clin-
ical experience, convenience, patient preference, route of
administration, and cost. The issue of safety as a factor in
making the best choice of anti-TNF agent for patients with
RA should be clarified with the availability of more data
from clinical trial and practice experience, and from post-
marketing surveillance reports.
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